Arcus Biosciences, Inc. (RCUS) Stock

Arcus Biosciences, Inc. (RCUS) is a Healthcare stock trading at $24.30 (as of 2026-06-18), with a market capitalization of $3.19B and a trailing P/E of -8.0. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

Arcus Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on developing cancer therapies in the United States. Its pipeline includes agents such as etrumadenant, zimberelimab, domvanalimab, quemliclustat, and AB521 in early-to-mid clinical development, and it conducts related evaluations through collaborations including with Strata Oncology and AstraZeneca (with BVF Partners).

Valuation — source: SEC EDGAR (first-party)
Price$24.30
Market Cap$3.19B
P/E Ratio-8.0
EV / EBITDA-7.9
Price / Book6.08
Price / Sales13.50
DCF Value (model)$-64.75
DCF Upside vs Price-366.5%
Profitability & Growth — source: SEC EDGAR
Revenue (TTM)$247.00M
Net Margin-142.9%
Return on Equity-70.4%
Debt / Equity0.19
Current Ratio4.04
Revenue Growth (YoY)-4.3%
EPS Growth (YoY)4.8%
FCF Growth (YoY)175.0%
Financial Health — source: SEC EDGAR
Altman Z-Score1.69 (distress)
Valuation vs Sector & Industry
Stock P/E-8.0
Sector P/E (Healthcare)21.0
Industry P/E (Pharmaceutical Products)17.3
vs Sector-138.1%
vs Industry-146.3%
Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Top Institutional HolderGILEAD SCIENCES, INC. ($678.77M)
Institutional Holders Tracked10
Company
SectorHealthcare
IndustryPharmaceutical Products
CEOTerry J. Rosen
Employees627
CountryUS
IPO Date2018-03-15

Related Companies (Business model: Biotech (Clinical / Commercial-Stage); 8 closest by market cap; US-domiciled)

  • IDEAYA Biosciences, Inc. (IDYA)
  • Nuvation Bio Inc. (NUVB)
  • Disc Medicine, Inc. (IRON)
  • Mineralys Therapeutics, Inc. (MLYS)
  • Prestige Consumer Healthcare Inc. (PBH)
  • Catalyst Pharmaceuticals, Inc. (CPRX)
  • Supernus Pharmaceuticals, Inc. (SUPN)
  • Beam Therapeutics Inc. (BEAM)
RCUS earnings history · RCUS institutional & insider holders · Congress trades · Insider trades · Short interest · Stock screener

Data as of 2026-06-18.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.